Acquisitions, Quarterly Reports, and Stock Price Movements - Research Report on Santarus, Celgene, Pharmacyclics, Quest

 Acquisitions, Quarterly Reports, and Stock Price Movements - Research Report
     on Santarus, Celgene, Pharmacyclics, Quest Diagnostics, and Stryker

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Santarus,
Inc. (NASDAQ: SNTS), Celgene Corporation (NASDAQ: CELG), Pharmacyclics, Inc.
(NASDAQ: PCYC), Quest Diagnostics Inc. (NYSE: DGX), and Stryker Corporation
(NYSE: SYK). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Santarus, Inc. Research Report

On November 7, 2013, Santarus Inc. (Santarus) and Salix Pharmaceuticals Ltd.
(Salix Pharmaceuticals) announced that the Companies have entered into a
definitive merger agreement. Under the said agreement, Salix will acquire all
of the outstanding common stock of Santarus for $32.00 per share in cash
(without interest). Santarus reported that the all-cash transaction values the
Company at approximately $2.6 billion and the $32.00 per share price
represents an approximately 36% premium over Santarus' November 6, 2013
closing price of $23.53 per share and an approximately 39% premium over
Santarus' average closing price for the prior 30-day period. Gerald T. Proehl,
CEO, Santarus, said, "We believe the timing is right for this strategic
combination with Salix, a highly respected company that is uniquely positioned
to expand the commercialization of Santarus' marketed products and to continue
to advance the development of our pipeline products. We welcome the
opportunity Salix will provide to build on Santarus' success." The Boards of
Directors of Salix and Santarus have unanimously approved the proposed
transaction. The Companies expect the transaction to close in Q1 2014. The
Full Research Report on Santarus, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/22f8_SNTS]

--

Celgene Corporation Research Report

On November 7, 2013, Celgene International Sàrl, a wholly-owned subsidiary of
Celgene Corporation (Celgene), announced that data from FIRST (Frontline
Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide),
its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in
combination with dexamethasone in patients newly diagnosed with multiple
myeloma (NDMM) ineligible for stem cell transplant will be presented on
December 8, 2013, during the plenary session of the 55^th American Society of
Hematology annual meeting in New Orleans, Louisiana. Celgene added that
abstracts for the meeting have been released at the Society's website, and
will be published in the journal Blood. Celgene further revealed that after a
median follow-up of 37 months, the trial met its primary endpoint (PFS),
demonstrating a 28% reduction in risk of progression or death (HR=0.72; p=
0.00006). Celgene further informed that the preplanned interim analysis of
overall survival demonstrated a 22% reduction in risk of death in favor of Arm
A vs. Arm C (HR=0.78, p=0.01685), without crossing the pre-specified boundary
(p<0.0096). Celgene further reported that all other secondary endpoints
consistently showed improvement in favor of Arm A vs. Arm C; ORR (partial
response or better) 75% vs. 62% (p < 0.00001), DOR (HR=0.63; p<0.00001), and
PFS2 (HR=0.78, p=0.0051). The Full Research Report on Celgene Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7f47_CELG]

--

Pharmacyclics, Inc. Research Report

On November 7, 2013, Pharmacyclics Inc. (Pharmacyclics) reported its Q3 2013
financial results. The Company's total revenue declined 23.0% YoY to $79.1
million during the quarter. Net income was $42.3 million or $0.55 per diluted
share in Q3 2013, compared to net income of $75.6 million or $1.02 per diluted
share in Q3 2012. Commenting on the results, Bob Duggan, Pharmacyclics CEO and
Chairman of the Board said, "Team Pharmacyclics has consistently improved
enrollment and data submission timelines for our CLL and MCL studies over the
past years. Often the clinical accomplishments are ahead of our internal
expectation. Most recently we achieved an important milestone with ibrutinib's
drug application now being submitted to the European authorities. Together
with Janssen, our partner, we are working towards a broad clinical advancement
of ibrutinib and have now focused in on making the product commercially
available in all major markets around the world. Over the next several
quarters, we are anticipating additional clinical and regulatory progress. We
are on our way to becoming a true ally for patients and physicians, addressing
serious, unmet medical health care needs for patients." The Full Research
Report on Pharmacyclics, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/df74_PCYC]

--

Quest Diagnostics Inc. Research Report

On November 8, 2013, Quest Diagnostics Inc.'s (Quest Diagnostics) stock
declined 0.60%, ending the day at $63.32. Over the previous three trading
sessions, shares of Quest Diagnostics gained 1.07%, outperforming the S&P 500
which gained 0.43% during the same period. The Full Research Report on Quest
Diagnostics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/05ba_DGX]

--

Stryker Corporation Research Report

On November 8, 2013, Stryker Corporation's (Stryker) stock rose 0.59%, ending
the day at $73.33. Over the previous three trading sessions, shares of Stryker
declined 0.97%, compared to the S&P 500 which gained 0.43% during the same
period. The Full Research Report on Stryker Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5b34_SYK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.